%0 Journal Article
%T Effectiveness of a 23-valent pneumococcal polysaccharide vaccine for the prevention of pneumococcal pneumonia in the elderly with chronic respiratory diseases: a case-control study of a single center.
%A Masuda T
%A Nakatani E
%A Shirai T
%A Akamatsu T
%A Tamura K
%A Takahashi S
%A Tanaka Y
%A Watanabe H
%A Endo Y
%A Suzuki T
%A Saigusa M
%A Yamamoto A
%A Morita S
%A Sato Y
%A Asada K
%J BMC Pulm Med
%V 21
%N 1
%D Apr 2021 16
%M 33863300
%F 3.32
%R 10.1186/s12890-021-01491-w
%X <B>BACKGROUND: </B>The effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in preventing pneumococcal pneumonia has been controversial.<BR><B>METHODS: </B>To evaluate the effectiveness of the PPSV23 in elderly outpatients with chronic respiratory diseases, we carried out a case-control study, including 4128 outpatients aged ≥ 65 years, in the respiratory department.<BR><B>RESULTS: </B>There were 320 vaccinated patients, of which 164 were diagnosed with pneumococcal pneumonia. The adjusted odds ratio was 0.39 (95% confidence interval (CI), 0.17 to 0.89). In the subsets consisting of age groups ≥ 70 and ≥ 75 years, the adjusted odds ratio (95% CI) was respectively 0.16 (0.04 to 0.67) and 0.15 (0.02 to 1.12).<BR><B>CONCLUSIONS: </B>This real-world study suggests that PPSV23 can be useful in preventing pneumococcal pneumonia in the elderly with chronic respiratory diseases.